#AAN2018 – Olesoxime Stabilizes SMA Patients’ Long-term Movement Function, Extension Study Shows
Olesoxime (TRO19622) stabilizes the movement function of patients with Type 2 or Type 3 spinal muscular atrophy over the long term, an extension of a Phase 2 clinical trial shows.